Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial

Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial

308273

Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial

Once-a-day treatment with oral ANVS401 was found to significantly improve motor skills among Parkinson’s disease patients in a Phase 2a clinical trial. Annovis Bio, the company developing ANVS401, is now planning to meet with the U.S. Food and Drug Administration (FDA) to discuss possibly initiating larger Phase 3 studies. “We are thrilled by these improvements in motor function of PD [Parkinson’s disease] patients,” Maria Maccecchini, PhD, the founder, president, and CEO of Annovis, said in a press…

You must be logged in to read/download the full post.